» Articles » PMID: 39391521

Optimising Antidiabetic Medication Management for Type 2 Diabetes and Renal Dysfunction in Can Tho City, Vietnam

Overview
Publisher Termedia
Date 2024 Oct 11
PMID 39391521
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The research aimed to delineate and investigate the utilisation of antidiabetic drugs in type 2 diabetes patients with kidney failure at a hospital in Can Tho City, Vietnam.

Material And Methods: The research analysed the use of antidiabetic drugs at various time points, determined the drug interaction rate, and evaluated the appropriate use of drugs and the relationship with the achievement of target blood glucose and HbA levels. A two-tailed Student's t-test was employed to compare continuous variables, an ANOVA test was used to assess multiple values, and an χ test was utilised to evaluate categorical variables.

Results: Insulin monotherapy was the predominant regimen for treating type 2 diabetes in patients with impaired kidney function. Metformin was the most prescribed oral medication. Approximately 85.78% of patients received safe and appropriate diabetes treatment. Statistical analysis revealed a significant relationship between achieving target blood glucose and HbA after 3 months and factors such as safe drug use and minimal drug interactions (p < 0.05). Patients with chronic kidney disease demonstrated better blood glucose control compared to those with acute kidney disease.

Conclusions: The most common drug used for type 2 diabetes patients with impaired kidney function was insulin monotherapy, with usage increasing with the severity of chronic kidney disease. The chronic kidney disease group exhibited a higher rate of achieving target blood glucose and HbA compared to the acute kidney disease group. Rational, safe, and interaction-free drug use significantly contributed to better blood sugar control compared to less prudent medication choices.

References
1.
Majumder A, RoyChaudhuri S, Sanyal D . A Retrospective Observational Study of Insulin Glargine in Type 2 Diabetic Patients with Advanced Chronic Kidney Disease. Cureus. 2020; 11(11):e6191. PMC: 6919959. DOI: 10.7759/cureus.6191. View

2.
Pan X, Lin X, Huang X, Xu J, Ye L, Zhang T . The Burden of Diabetes-Related Chronic Kidney Disease in China From 1990 to 2019. Front Endocrinol (Lausanne). 2022; 13:892860. PMC: 9240757. DOI: 10.3389/fendo.2022.892860. View

3.
Wang Y, Ding L, Wang R, Guo Y, Yang Z, Yu L . Circ_0004951 Promotes Pyroptosis of Renal Tubular Cells the NLRP3 Inflammasome in Diabetic Kidney Disease. Front Med (Lausanne). 2022; 9:828240. PMC: 9207212. DOI: 10.3389/fmed.2022.828240. View

4.
Adler A, Stevens R, Manley S, Bilous R, Cull C, Holman R . Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2002; 63(1):225-32. DOI: 10.1046/j.1523-1755.2003.00712.x. View

5.
Rhee J, Han J, Montez-Rath M, Kim S, Cullen M, Stafford R . Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease. J Diabetes Complications. 2019; 33(11):107423. PMC: 6823164. DOI: 10.1016/j.jdiacomp.2019.107423. View